I-4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Ubunyulu > 98.5% (HPLC) I-Lenvatinib Mesylate Intermediate Factory
I-Ruifu Chemical Supply Lenvatinib Mesylate Intermediate with High Purity
Lenvatinib Mesylate CAS 857890-39-2
I-4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
I-Desquinolinyl Lenvatinib;I-1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
I-4-Amino-3-Chlorophenol CAS 17609-80-2
I-4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Igama leMchiza | I-4-Chloro-7-Methoxyquinoline-6-Carboxamide |
Izithethantonye | I-4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Ukungcola kweLenvatinib 12;Ukungacoceki kweLenvatinib B;Lenvatinib Ukungcola LFS-B |
Inombolo yeCAS | 417721-36-9 |
Inombolo yeCAT | RF-PI1971 |
Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ye-50MT / Year |
Ifomula yeemolekyuli | I-C11H9ClN2O2 |
Ubunzima beMolekyuli | 236.65 |
Indawo yokunyibilika | >205℃ (ngoDisemba) |
Ukuxinana | 1.380±0.060 g/cm3 |
Uphawu | Ruifu Chemical |
Into | Iinkcukacha |
Imbonakalo | I-Off-White ukuya kwiPowder eKhanyayo etyheli |
Ubunyulu / Indlela yokuHlalutya | >98.5% (HPLC) |
Ilahleko ekomisweni | <0.50% |
Intsalela kwi-Ignition | <0.50% |
Ukungcola ngokupheleleyo | <1.50% |
Proton NMR Spectrum | Iyahambelana noLwakhiwo |
Umgangatho woVavanyo | Umgangatho woShishino |
Ukusetyenziswa | Umbindi weLenvatinib Mesylate (CAS: 857890-39-2) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma
I-4-Chloro-7-Methoxyquinoline-6-Carboxamide (i-CAS: 417721-36-9) isetyenziswa kakhulu njenge-intermediate ye-Lenvatinib Mesylate (CAS: 857890-39-2).Iphuhliswe yi-Eisai Inc., i-lenvatinib mesylate yi-vascular endothelial growth factor receptor (VEGF) inhibitor enomsebenzi ochasene ne-VEGF subtypes 1, 2, kunye ne-3 kwaye yamkelwa yi-FDA kwi-2015 yonyango lomhlaza we-thyroid owahlukileyo okhoyo ekuhlaleni. iphindaphinda, i-metastatic, okanye iqhubela phambili kwaye ayizange iphendule kunyango lwe-iodine ye-radioactive.NgoMeyi ka-2016, i-FDA yavuma ichiza njengonyango oludityanisiweyo kunye ne-everolimus kunyango lwe-advanced renal cell carcinoma.Ngenxa yokuba i-VEGF (kunye ne-fibroblast growth factor receptors, eyaziwa ngokuba yi-FGFRs) icingelwa ukuba idlala indima kwi-cardiovascular signaling pathways, i-VEGF2R kunye ne-FGFR inhibition kucingelwa ukuba ziinkqubo ezisemva kwesiphumo sokuqala se-lenvatinib mesylate, i-hypertension.